Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review
- PMID: 32622478
- DOI: 10.1016/j.currproblcancer.2020.100614
Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a devastating malignant neoplasm with dismal outcomes. Several therapeutic modalities have been used with variable success to downsize these tumors for resection. Neoadjuvant therapy such as chemoembolization and radioembolization offer promising options to manage tumor burden prior to resection. A systematic review of the literature was performed with a focus on conversion therapy for ICC and tumor downsizing to increase resection rates among patients who have an initially unresectable tumor. Of 132 patients with initially unresectable ICC, we identified 27 who underwent conversion therapy with surgical resection. Adequate tumor downsizing was achieved with chemotherapy, chemoembolization, radioembolization, or combination thereof. Although negative tumor margins were possible in some patients, recurrence rates and survival outcomes were inconsistently reported. Twenty-three of 27 patients were alive at last reported follow-up. Conversion therapy for initially unresectable ICC may offer adequate tumor downsizing for resection.
Keywords: Chemoembolization; Cholangiocarcinoma; Conversion therapy; Liver neoplasms; Neoadjuvant therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study.Cardiovasc Intervent Radiol. 2019 Dec;42(12):1709-1717. doi: 10.1007/s00270-019-02344-0. Epub 2019 Oct 2. Cardiovasc Intervent Radiol. 2019. PMID: 31578633
-
Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.Eur J Surg Oncol. 2015 Jan;41(1):120-7. doi: 10.1016/j.ejso.2014.09.007. Epub 2014 Oct 7. Eur J Surg Oncol. 2015. PMID: 25449754 Free PMC article. Review.
-
Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: Development of a prognostic nomogram.Hepatobiliary Pancreat Dis Int. 2020 Apr;19(2):138-146. doi: 10.1016/j.hbpd.2020.02.005. Epub 2020 Feb 21. Hepatobiliary Pancreat Dis Int. 2020. PMID: 32139295
-
Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: a case report.Anticancer Res. 2008 Sep-Oct;28(5B):2987-90. Anticancer Res. 2008. PMID: 19031944
-
Locoregional therapy for cholangiocarcinoma.Curr Opin Gastroenterol. 2013 May;29(3):324-8. doi: 10.1097/MOG.0b013e32835d9dea. Curr Opin Gastroenterol. 2013. PMID: 23337933 Review.
Cited by
-
Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma.Surg Case Rep. 2024 Feb 9;10(1):35. doi: 10.1186/s40792-024-01832-x. Surg Case Rep. 2024. PMID: 38332333 Free PMC article.
-
Imaging features based on CT and MRI for predicting prognosis of patients with intrahepatic cholangiocarcinoma: a single-center study and meta-analysis.Cancer Imaging. 2023 Jun 7;23(1):56. doi: 10.1186/s40644-023-00576-5. Cancer Imaging. 2023. PMID: 37287062 Free PMC article.
-
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.Front Immunol. 2023 Jan 9;13:1079342. doi: 10.3389/fimmu.2022.1079342. eCollection 2022. Front Immunol. 2023. PMID: 36700218 Free PMC article. Review.
-
Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade.Cancers (Basel). 2022 Sep 3;14(17):4320. doi: 10.3390/cancers14174320. Cancers (Basel). 2022. PMID: 36077855 Free PMC article.
-
Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.Front Oncol. 2021 Nov 24;11:751391. doi: 10.3389/fonc.2021.751391. eCollection 2021. Front Oncol. 2021. PMID: 34900698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
